| Expression pattern: |
UP |
| Associated gene: |
CDCA3, Ago2 |
| Associated microRNA: |
miR-512-3p |
| Biological function: |
Promotes TNBC cell proliferation, migration, invasion/metastasis, tumor growth in vivo, and doxorubicin resistance; inhibits doxorubicin-induced apoptosis when highly expressed. |
| Molecular mechanism: |
Acts as a cytoplasmic miRNA sponge for miR-512-3p, thereby relieving miR-512-3p-mediated repression of CDCA3 and increasing CDCA3 expression. |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); apoptosis (inhibits); chemoresistance (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Transfection; CCK8; Colony Formation Assay; Transwell Assay; Annexin V/PI Flow Cytometry; Western Blot; RNA Pull-Down; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); In Vivo Animal Model; Survival Analysis |
| Clinical significance: |
High circUBE2D2 expression is associated with advanced TNM stage, lymph node metastasis, and poorer overall survival (adverse prognosis) in TNBC patients. |
| Description: |
circUBE2D2 (hsa_circ_0005728) is up-regulated in TNBC and mainly localized in the cytoplasm. It promotes malignant phenotypes (proliferation, migration/invasion, tumor growth) and doxorubicin chemoresistance by sponging miR-512-3p, thereby up-regulating CDCA3. |
| Confidence score: |
0.8591 |